QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ma, J. M Articles by Yeo, E. Search for Related Content PubMed PubMed Citation Articles by Ma, J. M Articles by Yeo, E.

ANTICOAGULATION

Anti-Xa Monitoring of Enoxaparin for Acute Coronary Syndromes in Patients with Renal Disease

Clinical Pharmacist, Department of Pharmaceutical Services, Toronto East General Hospital, Toronto, Ontario, Canada

Cynthia A Jackevicius, PharmD FCSHP

Pharmacist, Pharmacy Department, University Health Network; Assistant Professor, Faculty of Medicine, University of Toronto; Adjunct Scientist, Institute for Clinical Evaluative Sciences, Toronto

Erik Yeo, MD FRCPC

Head, Laboratory Hematology & Hematopathology; Director, Hemostasis and Thrombosis, University Health Network & Toronto Medical Laboratories, Toronto

Reprints: Jessica M Ma BScPhm, Department of Pharmaceutical Services, Toronto East General Hospital, 825 Coxwell Ave., Toronto, Ontario M4C 3E7, Canada, fax 416/469-6325, jesma{at}tegh.on.ca

BACKGROUND: There are limited data on dosing of enoxaparin in patients with renal disease due to the routine exclusion of this population in clinical trials. To account for the potentially delayed drug elimination in these patients, we developed guidelines for adjusting enoxaparin dosing based on anti-Xa monitoring.

OBJECTIVE: To evaluate anti-Xa level monitoring, resulting from the standards of practice as set out by our hospital's guidelines for enoxaparin dosing in renally impaired patients.

METHODS: A total of 72 separate acute coronary syndrome patient admissions were retrospectively reviewed. All patients had anti-Xa levels taken and creatinine clearance values <30 mL/min during enoxaparin therapy.

RESULTS: The average trough anti-Xa level at the once- and twice-daily doses was 0.40 and 0.72 IU/mL, respectively. With twice-daily dosing, only 6% of the trough concentrations were in the target range of 0.2–0.3 IU/mL compared with 36% with once-daily dosing. Of the 22 patients who had a change of dosing frequency from twice to once daily, 5% of trough anti-Xa levels were 0.5 IU/mL with twice-daily versus 68% with once-daily dosing.

CONCLUSIONS: Although the relationship between anti-Xa activity, efficacy, and adverse effects has not been definitively established, anti-Xa levels can assist with dosing of enoxaparin in renally impaired patients. Our hospital guidelines are effective in adjusting dosing to reach target anti-Xa levels.

Key Words: acute coronary syndromes, enoxaparin, low-molecular-weight heparin

Published Online, August 24, 2004. www.theannals.com, DOI 10.1345/aph.1E096

This article has been cited by other articles:

				A. P. Wheeler and T. W. Rice Coagulopathy in Critically III Patients: Part 2-Soluble Clotting Factors and Hemostatic Testing Chest, January 1, 2010; 137(1): 185 - 194. [Abstract] [Full Text] [PDF]

				E. A Nutescu, S. A Spinler, A. Wittkowsky, and W. E Dager Low-Molecular-Weight Heparins in Renal Impairment and Obesity: Available Evidence and Clinical Practice Recommendations Across Medical and Surgical Settings Ann. Pharmacother., June 1, 2009; 43(6): 1064 - 1083. [Abstract] [Full Text] [PDF]

				W. Lim, F. Dentali, J. W. Eikelboom, and M. A. Crowther Meta-Analysis: Low-Molecular-Weight Heparin and Bleeding in Patients with Severe Renal Insufficiency Ann Intern Med, May 2, 2006; 144(9): 673 - 684. [Abstract] [Full Text] [PDF]